Nebenwirkungen · Wegovy
Wegovy 1.5 mg tablets Wegovy 4 mg tablets Wegovy 9 mg tablets Wegovy 25 mg tablets · Abschnitt 4.8 · PDF-Seite 48
HOS-147372 · Präparat HOS-099634
Diabetic retinopathy in patients with type 2 diabetes A 2-year clinical trial investigated subcutaneous semaglutide 0.5 mg and 1 mg vs. placebo in 3 297 patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose. In this trial, adjudicated events of diabetic retinopathy complications occurred in more patients treated with semaglutide (3.0%) compared to placebo (1.8 %). This was observed in insulin-treated patients with known diabetic retinopathy. The treatment difference appeared early and persisted throughout the trial. In STEP 2, retinal disorders were reported by 6.9% of patients treated with semaglutide 2.4 mg, 6.2 % of patients treated with subcutaneous semaglutide 1 mg, and 4.2% of patients treated with placebo. The majority of events were reported as diabetic retinopathy (4.0%, 2.7%, and 2.7%, respectively) and non-proliferative retinopathy (0.7%, 0%, and 0%, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage 2ff70c6ab8f6463a6e982c81c021502f980fc06ba52bf4695ba8e7b90621f20c · Zeichen 9761–10719 im Abschnitt